• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by ObsEva SA

    3/28/23 4:41:01 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OBSV alert in real time by email
    POS AM 1 d492940dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on March 28, 2023

    Registration No. 333-268723

    Registration No. 333-266492

    Registration No. 333-262820

    Registration No. 333-260974

    Registration No. 333-233069

    Registration No. 333-222820

    Registration No. 333-221462

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT TO:

    Form F-3 Registration No. 333-268723

    Form F-3 Registration No. 333-266492

    Form F-3 Registration No. 333-262820

    Form F-3 Registration No. 333-260974

    Form F-3 Registration No. 333-233069

    Form F-3 Registration No. 333-222820

    Form F-3 Registration No. 333-221462

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    OBSEVA SA

    (Exact name of Registrant as specified in its charter)

     

     

     

    Switzerland   N/A

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Chemin des Aulx, 12

    1228 Plan-les-Ouates

    Geneva, Switzerland

    Tel: +41 22 552 38 40

    (Address and telephone number, including area code of Registrant’s principal executive offices)

     

     

    Cogency Global Inc.

    122 East 42nd Street, 18th Floor

    New York, New York 10168

    Tel: (212) 947-7200

    (Name, address, including zip code, and telephone number, of agent for service)

     

     

    Copies to:

    Divakar Gupta

    Ryan Sansom

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    Tel: (212) 479-6000

     

     

    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statements.

    If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

    Emerging growth company  ☐

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

    †

    The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

    This post-effective amendment will become effective in accordance with the provisions of Section 8(c) of the Securities Act.

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the following Registration Statements on Form F-3 (each a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities Exchange Commission (the “SEC”) by ObsEva SA (the “Registrant”):

     

      •  

    Registration Statement No.  333-268723, filed with the SEC on December 9, 2022;

     

      •  

    Registration Statement No.  333-266492, filed with the SEC on August 3, 2022;

     

      •  

    Registration Statement No.  333-262820, filed with the SEC on February 17, 2022; as amended by that certain Post-Effective Amendment No. 1 to the Registration Statement on Form F-3, filed with the SEC on February 25, 2022;

     

      •  

    Registration Statement No.  333-260974, filed with the SEC on November 10, 2021;

     

      •  

    Registration Statement No.  333-233069, filed with the SEC on August 7, 2019;

     

      •  

    Registration Statement No.  333-222820, filed with the SEC on February 1, 2018, as amended by that certain Post-Effective Amendment No. 1 to the Registration Statement on Form F-3, filed with the SEC on February 23, 2018, and that certain Post-Effective Amendment No. 2 to the Registration Statement on Form F-3, filed with the SEC on March 1, 2018; and

     

      •  

    Registration Statement No.  333-221462, filed with the SEC on November 9, 2017, as amended by that certain Post-Effective Amendment No. 1 to Form F-1 on Form F-3 Registration Statement, filed with the SEC on March 1, 2018.

    The Registrant is filing this Post-Effective Amendment to deregister any and all securities that remain unsold under the Registration Statements as of the date hereof. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment to the Registration Statements on Form F-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in Geneva, Switzerland, on March 28, 2023.

     

    OBSEVA SA
    By:  

    /s/ Will Brown

     

    Name:  Will Brown

     

    Title:   Interim Chief Executive Officer and Chief Financial Officer

     

    II-1


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of ObsEva SA, has signed this Post-Effective Amendment to Registration Statements on Form F-3 on March 28, 2023.

     

    Authorized U.S. Representative – Cogency Global Inc.

    By:  

    /s/ Colleen A. DeVries

     

    Name:  Colleen A. DeVries

     

    Title:   Senior Vice-President on behalf of Cogency Global Inc.

     

    II-2

    Get the next $OBSV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OBSV

    DatePrice TargetRatingAnalyst
    8/30/2022Buy → Neutral
    H.C. Wainwright
    6/3/2022$6.00Overweight
    Cantor Fitzgerald
    4/26/2022$12.00Buy
    Canaccord Genuity
    3/28/2022$12.00Buy
    Aegis Capital
    11/29/2021$17.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OBSV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ObsEva Files Year End 2022 Financial Statements

    ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20

    3/31/23 4:01:00 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd

    3/15/23 7:00:00 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

    3/13/23 7:00:00 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OBSV
    SEC Filings

    View All

    SEC Form 15-12G filed by ObsEva SA

    15-12G - ObsEva SA (0001685316) (Filer)

    4/26/23 7:00:50 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - ObsEva SA (0001685316) (Filer)

    4/11/23 4:01:29 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ObsEva SA

    10-K - ObsEva SA (0001685316) (Filer)

    3/31/23 4:01:50 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OBSV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ObsEva downgraded by H.C. Wainwright

    H.C. Wainwright downgraded ObsEva from Buy to Neutral

    8/30/22 7:29:47 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on ObsEva with a new price target

    Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00

    6/3/22 7:29:31 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on ObsEva with a new price target

    Canaccord Genuity initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00

    4/26/22 6:26:53 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OBSV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Loumaye Ernest

    4 - ObsEva SA (0001685316) (Issuer)

    4/11/23 4:02:23 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Loumaye Ernest bought $440,000 worth of shares (4,000,000 units at $0.11), increasing direct ownership by 200% to 6,000,000 units

    4 - ObsEva SA (0001685316) (Issuer)

    3/2/23 4:16:42 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Brown William Michael

    4 - ObsEva SA (0001685316) (Issuer)

    2/24/23 4:50:38 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OBSV
    Financials

    Live finance-specific insights

    View All

    ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

    -Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange                 GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharma

    5/17/22 7:00:00 AM ET
    $OBSV
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

    GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576. The webcast can be accessed live here and will also be accessible under "Events Calendar" in the investors section of ObsEva's website. The webcast will be archived on the company

    5/12/22 7:00:00 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

    -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in sec

    1/6/22 7:00:00 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OBSV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by ObsEva SA

    SC 13D - ObsEva SA (0001685316) (Subject)

    4/17/23 5:00:00 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ObsEva SA (Amendment)

    SC 13G/A - ObsEva SA (0001685316) (Subject)

    2/14/23 4:18:58 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - ObsEva SA (0001685316) (Subject)

    3/4/21 6:13:21 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OBSV
    Leadership Updates

    Live Leadership Updates

    View All

    ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

    3/13/23 7:00:00 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

    GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. "We could not be more pleased, or fortunate, to have

    5/19/22 7:05:00 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra

    5/2/22 7:00:00 AM ET
    $EVFM
    $OBSV
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care